195 related articles for article (PubMed ID: 35538663)
21. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract][Full Text] [Related]
22. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
23. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
24. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
25. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
26. Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma.
Li M; Long S; Hu J; Wang Z; Geng C; Ou S
Aging (Albany NY); 2019 Nov; 11(21):9405-9423. PubMed ID: 31692451
[TBL] [Abstract][Full Text] [Related]
27. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
28. Identification of a panel of genes as a prognostic biomarker for glioblastoma.
Wang F; Zheng Z; Guan J; Qi D; Zhou S; Shen X; Wang F; Wenkert D; Kirmani B; Solouki T; Fonkem E; Wong ET; Huang JH; Wu E
EBioMedicine; 2018 Nov; 37():68-77. PubMed ID: 30341039
[TBL] [Abstract][Full Text] [Related]
29. PBK as a Potential Biomarker Associated with Prognosis of Glioblastoma.
Dong C; Fan W; Fang S
J Mol Neurosci; 2020 Jan; 70(1):56-64. PubMed ID: 31617063
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro.
Bernhart E; Damm S; Wintersperger A; DeVaney T; Zimmer A; Raynham T; Ireson C; Sattler W
Exp Cell Res; 2013 Aug; 319(13):2037-2048. PubMed ID: 23562655
[TBL] [Abstract][Full Text] [Related]
31. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
32. Expression and clinical significance of CPS1 in glioblastoma multiforme.
Wu G; Yan Y; Zhou Y; Wang X; Wei J; Chen X; Lin W; Ou C; Zhou J; Xu Z
Curr Res Transl Med; 2019 Nov; 67(4):123-128. PubMed ID: 31492588
[TBL] [Abstract][Full Text] [Related]
33. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
34. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
35. lncRNA and mRNA signature for prognosis prediction of glioblastoma.
Liu G; Pan Y; Li Y; Xu H
Future Oncol; 2020 May; 16(13):837-848. PubMed ID: 32250161
[No Abstract] [Full Text] [Related]
36. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
37. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
38. Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme.
Erkutlu I; Cigiloglu A; Kalender ME; Alptekin M; Demiryurek AT; Suner A; Ozkaya E; Ulasli M; Camci C
Tumour Biol; 2013 Apr; 34(2):1139-44. PubMed ID: 23338717
[TBL] [Abstract][Full Text] [Related]
39. 3D spatial organization and network-guided comparison of mutation profiles in Glioblastoma reveals similarities across patients.
Dincer C; Kaya T; Keskin O; Gursoy A; Tuncbag N
PLoS Comput Biol; 2019 Sep; 15(9):e1006789. PubMed ID: 31527881
[TBL] [Abstract][Full Text] [Related]
40. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
